X0306
4
2014-08-05
0
0001365216
Sucampo Pharmaceuticals, Inc.
SCMP
0001384370
Ueno Ryuji
4520 EAST-WEST HIGHWAY
SUITE 300
BETHESDA
MD
20814
0
0
1
0
Class A Common Stock
2014-08-05
4
S
0
84243
6.2408
D
22558286
I
By S&R Technology Holdings, LLC
Class A Common Stock
2014-08-06
4
S
0
30523
6.3231
D
22527763
I
By S&R Technology Holdings, LLC
Class A Common Stock
2014-08-07
4
S
0
66961
6.3148
D
22460802
I
By S&R Technology Holdings, LLC
Class A Common Stock
353530
D
Class A Common Stock
60357
I
By Wife
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on September 11, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.13 to $6.37, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
S&R Technology Holdings, LLC is wholly owned by Dr. Ueno and his wife. Dr. Ueno disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.02 to $6.41, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.46, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Dr. Ueno disclaims beneficial ownership of the reported securities.
/s/ Kei Tolliver, by Power of Attorney
2014-08-07